Company Overview
MeiraGTx Holdings plc operates as a clinical stage genetics medicines company dedicated to developing treatments for patients suffering from serious diseases. The enterprise specifically focuses its therapeutic development on ocular conditions, including inherited retinal diseases and large degenerative ocular diseases, as well as neurodegenerative disease. Within the broader financial landscape, the company functions within the Healthcare sector and the Biotechnology industry, a classification that implies a focus on high-risk, high-reward research and development with long timelines to commercialization. As of the latest reporting period, the company holds a market capitalization of $596.44M and employs 409 individuals to execute its research and development strategies. The annual revenue for the trailing twelve months stands at $27.42M, indicating that the company generates limited commercial income relative to its operational scale. These financial figures suggest that MeiraGTx is a small-cap biotechnology firm that is heavily reliant on the successful progression of its clinical pipeline to achieve significant profitability, rather than current sales volume driving its valuation.
Financial Health
For the trailing twelve months, the company reported revenue of $27.42M, a net income of $-168,688,000, and an EBITDA of $-151,432,000. The substantial gap between the positive revenue of $27.42M and the significant negative net income of $-168,688,000 reveals a cost structure where operating expenses far exceed total sales, a characteristic common in clinical-stage biotechnology companies prior to product launch. The free cash flow stands at $-60,844,876, indicating that the company is burning through its cash reserves to fund its research and development activities. With cash holdings of $14.84M against total debt of $88.06M, the company's liquidity position is constrained, requiring ongoing capital raises or successful asset sales to maintain operations. The balance sheet appears leveraged rather than conservative, as total debt of $88.06M exceeds the cash balance of $14.84M, and the debt-to-equity ratio is listed as N/A due to the negative equity position. The current ratio is 0.22, which indicates that the company's current assets are less than half of its current liabilities, signaling potential short-term liquidity challenges if cash flows do not improve. Return on Equity is -611.4% and Return on Assets is -41.9%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the context of generating positive returns.
Valuation Assessment
The company presents a trailing P/E ratio of N/A and a forward P/E of -2.95, implying that earnings are currently negative and that the forward metric is based on projected negative earnings or a specific accounting adjustment rather than traditional profitability. The price-to-book ratio is -14.70, which indicates that the market is valuing the company at a negative multiple of its book value, reflecting the significant liabilities and lack of retained earnings. The price-to-sales ratio is 21.75, while the EV/EBITDA stands at -4.42; these alternative valuation metrics suggest that the market is pricing the stock based on asset value or pipeline potential rather than current cash generation or earnings power. The 52-week high is $9.73 and the 52-week low is $4.55, providing a trading range within which the current price fluctuates. To determine the precise position within this range, one must compare the current market price to these bounds, though the specific current price is not provided in the available facts to calculate the exact percentage deviation. The beta is 1.40, which means the stock exhibits higher volatility than the broader market, moving 40% more than the market average during periods of fluctuation. This elevated beta suggests that price movements will be more pronounced than those of large-cap healthcare peers, introducing additional risk for holders.
Growth & Income
The company experienced a revenue growth rate of -96.2% year over year, while the earnings growth rate is N/A due to the absence of positive earnings in the prior period. The decline in revenue indicates a contraction in commercial sales, and without positive earnings growth to offset this, the financial trajectory reflects a reduction in top-line performance rather than an expansion of profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders. Instead of paying dividends, the company reinvests its limited earnings or raises capital to fund its clinical stage genetics medicines pipeline and operational expenses. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of current earnings or dividend distributions, relying entirely on future clinical success to alter the financial trajectory.